WO2025061035 - BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/061035
Publication Date
27.03.2025
International Application No.
PCT/CN2024/119418
International Filing Date
18.09.2024
Title **
[English]
BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF
[French]
COMPOSÉ D'AGENT DE DÉGRADATION SÉLECTIVE DE BRM ET SON UTILISATION
[Chinese]
BRM选择性降解剂化合物及其应用
Applicants **
NANJING ZAIMING PHARMACEUTICAL CO., LTD.
Inventors
ZENG, Fanxun
JIN, Jinghai
ZHU, Wei
LI, Yuewen
MAO, Jianping
LI, Zhengtao
TANG, Renhong
Priority Data
202311212766.1
19.09.2023
CN
202311627127.1
29.11.2023
CN
202410117813.2
26.01.2024
CN
202410612111.1
15.05.2024
CN
202411243441.4
05.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3196 | |
| EPO | Filing, Examination, Granting | 22563 | |
| Japan | Filing, Examination, Granting | 2640 | |
| South Korea | Filing, Examination, Granting | 3224 | |
| USA | Filing, Examination, Granting | 7190 |
Total:
38,813
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A BRM selective degradation agent compound. Specifically provided is a compound of formula (I), formula (I)-1, formula (I)-2 or formula (II), or a stereoisomer or a pharmaceutically acceptable salt thereof. The compound has the substituents and structural features described in the present application. Also described are a pharmaceutical composition comprising the compound of formula (I), formula (I)-1, formula (I)-2 or formula (II) or the stereoisomer thereof or the pharmaceutically acceptable salt thereof, and the use of the compound or the stereoisomer thereof or the pharmaceutically acceptable salt thereof in medicine.[French]
L'invention concerne un composé d'agent de dégradation sélective de BRM. L'invention concerne spécifiquement un composé de formule (I), de formule (I)-1, de formule (I)-2 ou de formule (II), ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci. Le composé présente les substituants et les caractéristiques structurales décrits dans la présente demande. L'invention concerne également une composition pharmaceutique comprenant le composé de formule (I), de formule (I)-1, de formule (I)-2 ou de formule (II) ou le stéréoisomère de celui-ci ou le sel pharmaceutiquement acceptable de celui-ci, et l'utilisation du composé ou du stéréoisomère de celui-ci ou du sel pharmaceutiquement acceptable de celui-ci en médecine.[Chinese]
一种BRM选择性降解剂化合物，具体提供了式(I)、式(I)-1、式(I)-2或式(II)的化合物或其立体异构体或其药学上可接受的盐，所述化合物具有本申请所述取代基和结构特征。还描述了包含式(I)、式(I)-1、式(I)-2或式(II)化合物或其立体异构体或其药学上可接受的盐的药物组合物，以及所述化合物或其立体异构体或其药学上可接受的盐在医药上的应用。